-
Mashup Score: 3
LINC 23 – We are joined by Principal Investigator, Dr Sahil Parikh (Columbia University Irving Medical Center, US) to discuss Abbott’s LIFE-BTK Randomised Controlled Trial. The
Source: www.radcliffevascular.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Coronary Bioresorbable Scaffolds Nearly as Safe and Effective as Conventional Metal Stents for Heart Disease Patients - 11 month(s) ago
May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI). These are significant findings from a global clinical trial led by a researcher from the Icahn School of Medicine at Mount Sinai. The work could…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @MtSinaiQueens @GreggWStone First-generation #BVS may be just as effective as drug-eluting metallic #stents, which are currently the standard treatment for #heartdisease patients undergoing percutaneous coronary intervention (#PCI): https://t.co/Vctss4K4Jp
-
-
Mashup Score: 2Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials - 2 year(s) ago
Background Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse events observed in conventional drug-eluting stents (DES) by dissolving once they have restored lasting patency. Objectives Compare the safety and efficacy of BVS versus DES in patients receiving percutaneous coronary intervention for coronary artery disease across a complete range of randomised…
Source: Open HeartCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Bioresorbable vascular scaffolds #BVS vs. conventional drug-eluting stents #DES across time: A #metaanalysis of RCTs @banerjeep https://t.co/XyDVI7XNMi https://t.co/AjEPC6Zv3E
-
-
Mashup Score: 0
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: EuroInterventionCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In this final 5-year report of the randomized AIDA trial, the excess risk of Absorb BVS on late adverse events, in particular device thrombosis, continued up to 4-years and plateaued afterwards. #EAPCI #BVS https://t.co/J3Y6wSzDs8 https://t.co/wgKApWJiFl
-
-
Mashup Score: 0Three‐year clinical outcomes with the ABSORB bioresorbable vascular scaffold in real life: Insights from the France ABSORB registry - 3 year(s) ago
Objectives The aim of this study was to determine the 3‐year outcomes of patients treated with Absorb bioresorbable vascular scaffold (BVS) implantation. Background Randomized trials and observati…
Source: Wiley Online LibraryCategories: Cardiology News and Journals, Latest HeadlinesTweet-
3-Year Outcomes from France ABSORB Registry -n=2070 -#BVS thrombosis 3% -TVR 7.6% -BVS length & 2.5 mm diameter a/w higher MACE -continued events up to 3 years https://t.co/e0lu4xhTsV Follow @CCIJournal, https://t.co/oEQYGH7lGw Official Journal of @SCAI https://t.co/BSRmtlUi2H
-
-
Mashup Score: 2
Background In this prespecified AIDA‐trial sub‐study we investigate the clinical performance of absorb bioresorbable vascular scaffold (BVS) compared to Xience everolimus‐eluting stent (EES) in rout…
Source: Wiley Online LibraryCategories: Cardiology News and Journals, Latest HeadlinesTweet-
AIDA Trial Substudy in Diabetics: -Absorb #BVS vs. Xience EES, 3 yr f/u -MACE 18.7% vs. 18.0% (p=0.84) -Device Thrombosis 4.8% vs. 0.7% (p=0.028) https://t.co/LMMxFZTsTu Follow @CCIJournal, https://t.co/oEQYGHoWy4 Official Journal of @SCAI https://t.co/j35S27CF0S
-
-
Mashup Score: 0Abbott Restarts Bioresorbable Stent Clinical Trials With New Esprit Below-the-knee Scaffold - 4 year(s) ago
September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company’s new Esprit BTK Everolimus Eluting Resorbable Scaffold System. This is the first Investigational Device Exemption (IDE) trial in the U.S.
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
Abbott Restarts Bioresorbable Stent Clinical Trials With New Esprit Below-the-knee Scaffold https://t.co/sw5HSwIQQY #Cardiotwitter #PAD #CLI #BVS #bioresorbablestents #cathlab #Interventional
-
#TCT2023 #LBT study highlights:#LifeBTK Nice video summarizing study design: https://t.co/jNbT1qz8t2 @sbrugaletta do you remember the #BVS concept? it has been redesigned and was investigated in #BTK. Do not miss the results at @TCTConference by @sahilparikhmd… https://t.co/6Z21dURm8w